Literature DB >> 12930426

One 10-core prostate biopsy is superior to two sets of sextant prostate biopsies.

K G Fink1, G Hutarew, A Pytel, B Esterbauer, A Jungwirth, O Dietze, N T Schmeller.   

Abstract

OBJECTIVES: To compare the efficiency of different transrectal ultrasonography (TRUS)-guided prostate biopsy techniques for detecting prostate cancer.
MATERIALS AND METHODS: In all, 81 prostates from radical prostatectomy were used and two consecutive sets of sextant biopsies and one 10-core biopsy taken in each specimen. The 10-core biopsy consisted of a sextant biopsy and four cores from the far lateral areas of the prostate. To simulate a transrectal biopsy procedure, all biopsies were taken under TRUS guidance.
RESULTS: In the first set of sextant biopsies 44 prostate cancers (54%) were detected and in the second set 51 (63%). Combining both sets of sextant biopsies 57 (70%) of the carcinomas were detected. One set of 10-core biopsies detected 66 (82%) of all prostate cancers. Overall, with the 10-core biopsies 16% more prostate tumours were diagnosed than with two consecutive sets of sextant biopsies. To find the same number of prostate cancers as with the 10-core technique, 14% of patients undergoing sextant biopsy would require a second set and 11% at least a third set of biopsies.
CONCLUSIONS: The 10-core prostate biopsy technique is superior to the commonly used sextant technique and could spare patients unnecessary repeated biopsy. Even after including a second set of sextant biopsies, the total detection rate with these 12 biopsies was inferior to the 10-core technique.

Entities:  

Mesh:

Year:  2003        PMID: 12930426     DOI: 10.1046/j.1464-410x.2003.04350.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  8 in total

1.  CUA guidelines on prostate biopsy methodology.

Authors:  Assaad El-Hakim; Sabri Moussa
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 2.  A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer.

Authors:  Stijn W T P J Heijmink; Hilco van Moerkerk; Lambertus A L M Kiemeney; J Alfred Witjes; Ferdinand Frauscher; Jelle O Barentsz
Journal:  Eur Radiol       Date:  2006-01-04       Impact factor: 5.315

3.  [Metastasis of prostate carcinoma to the lamina submucosa of the distal rectum in ulcerative colitis 2 years after transrectal prostate biopsy and radical prostatovesiculectomy].

Authors:  J Bernhardt; C Letzkus; M Kind; H B Reith; N Pfitzenmaier
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

4.  Transrectal ultrasound guided biopsy for detecting prostate cancer: can random biopsies be reduced using the 4-dimensional technique?

Authors:  Fawzi T Abul; Narayanaswamy Arun; Mona A Abu-Assi; Akram M Asbeutah
Journal:  Int Urol Nephrol       Date:  2007-02-17       Impact factor: 2.370

5.  A review of repeat prostate biopsies and the influence of technique on cancer detection: our experience.

Authors:  M R Quinlan; R G Casey; R Flynn; R Grainger; T E D McDermott; J A Thornhill
Journal:  Ir J Med Sci       Date:  2009-06-04       Impact factor: 1.568

6.  A comparison of prostate cancer detection rates by 12 or 6 core biopsy at different prostate-specific antigen densities in Korean men.

Authors:  Hyeon Jeong; Byong Chang Jeong; Cheol Kwak; Eunsik Lee; Sang Eun Lee; Tae Beom Kim
Journal:  World J Urol       Date:  2008-04-26       Impact factor: 4.226

7.  Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.

Authors:  A Latifoltojar; N Dikaios; A Ridout; C Moore; R Illing; A Kirkham; S Taylor; S Halligan; D Atkinson; C Allen; M Emberton; S Punwani
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-07-21       Impact factor: 5.554

Review 8.  [Interactions between radical prostatovesiculectomy and diagnosis of prostate cancer : A medical-historical inventory on the occasion of 20 years of robot-assisted treatment].

Authors:  Wolfgang Otto; Wolf F Wieland
Journal:  Urologe A       Date:  2021-08       Impact factor: 0.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.